Zhang Lab is devoted to using the cutting-edge genomics and bioinformatics technologies to study fundamental problems of cancer biology and tumor heterogeneity. The current main research directions include: 1) dissecting tumor microenvironment, especially the accurate composition and functional status of tumor-infiltrating immune cells; 2) dissecting the heterogeneity of the tumor microenvironment and its impact on patient treatment; 3) developing innovative bioinformatics tools and resources to analyze, integrate, and visualize genomic data.
Zemin Zhang is an Academician of the Chinese Academy of Sciences, a Fellow of the Academic Advisory Committee of the Chinese Academy of Medical Sciences, and a Fellow of the International Society for Computational Biology (ISCB). He received his Bachelor’s degree from the Department of Biology at Nankai University in 1988, and his Ph.D. in Biochemistry, Microbiology, and Molecular Biology from The Pennsylvania State University in 1995. He conducted postdoctoral research at the University of California, San Francisco (UCSF) from 1995 to 1998. From 1998 to 2014, he worked at Genentech, Inc., USA, where he served as Director of the Bioinformatics Department and Principal Scientist of Bioinformatics. During this period, his work focused on applying machine learning and high-throughput sequencing technologies to the discovery of anticancer drug targets and biomarkers. In 2014, he joined Peking University, where he was subsequently appointed as a Changjiang Distinguished Professor by the Ministry of Education and selected for the Overseas High-Level Talent Program of the Organization Department of the CPC Central Committee. Professor Zhang is the inventor of 70 granted patents and has made direct contributions to the original discovery of molecular targets for several cancer therapeutics currently in clinical trials. His research achievements have been published in Cell, Nature, Science, Nature Genetics, Nature Biotechnology, and Nature Medicine multiple times.His achievements have been recognized in China’s Top Ten Medical Science and Technology News in 2017, and have been selected among the Top Ten Advances in Bioinformatics in China in 2018, 2019, 2021, 2022, 2023, 2024, and 2025. He has received multiple honors, including the Cell Press China Annual Paper Awards (2017, 2019, 2020, 2021), the Cell Best Paper Award (2020), the First Prize of Beijing Municipal Natural Science Award (2020), and the First Prize for Outstanding Achievement in Natural Science Research from the Ministry of Education (2025).
张泽民实验室致力于用前沿的生物信息和基因组学来解决癌症生物学中的核心问题，专注于研究肿瘤微环境的底层特征，发现了肿瘤在微环境水平的异质性和潜在规律，推进其在药物疗效预测和靶点发现中的应用。实验室目前主要的研究方向包括：（1）研究肿瘤微环境特别是肿瘤浸润免疫细胞的精确组成、相互作用以及功能状态，并鉴定影响这些细胞功能的调控基因；（2）研究肿瘤微环境的异质性、及其对癌症病人治疗的影响；（3）开发原创的生物信息学工具和数据库，来进行大数据的整合、分析和可视化。
张泽民教授，中国科学院院士，中国医学科学院学术咨询委员会学部委员，国际计算生物学会会士。1988年本科毕业于南开大学生物系,1995年获美国宾州州立大学获得生物化学、微生物学与分子生物学专业博士学位;1995-1998年在美国旧金山加州大学进行博士后研究工作。1998年-2014年任职于美国GENENTECH公司，从事生物信息学研究,任生物信息学部主任,生物信息首席科学家。致力于应用机器学习和高通量测序等高新技术进行抗癌药靶和生物标记物的发现。2014年加入北京大学，先后获得了教育部长江特聘教授、中组部海外高层次人才等荣誉。张泽民教授是70个已获得授权的专利的发明人，在临床试验中的多项癌症治疗药物的分子靶标的原创发现中做出了直接贡献。已多次在Cell、Nature、Science、Nature Biotechnology、Nature Medicine、Cancer Cell等国际著名杂志上发表论文，并担任多家专业杂志的编委，包括Cell、Cancer Cell、Cancer Discovery和Cell Research等。相关成果入选2017年度中国十大医学科技新闻、2018、2019、2021、2022、2023、2024、2025年度中国生物信息学十大进展，获得细胞出版社2017、2019、2020、2021中国年度论文、2020年细胞杂志最佳论文、2020年度北京市科学技术奖自然科学一等奖、2025年度教育部科学研究优秀成果奖自然科学研究成果奖一等奖等。